125 related articles for article (PubMed ID: 19001158)
1. Fine-tuning the homeostasis of regulatory T cells: new mechanism of immunomodulatory therapy in multiple sclerosis.
Hofstetter HH; Stüve O; Hartung HP
Arch Neurol; 2008 Nov; 65(11):1417-8. PubMed ID: 19001158
[No Abstract] [Full Text] [Related]
2. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
[TBL] [Abstract][Full Text] [Related]
3. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
[TBL] [Abstract][Full Text] [Related]
5. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
[TBL] [Abstract][Full Text] [Related]
6. Measuring and management of anti-interferon beta antibodies in subjects with multiple sclerosis.
Farrell RA; Giovannoni G
Mult Scler; 2007 Jun; 13(5):567-77. PubMed ID: 17548434
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
[No Abstract] [Full Text] [Related]
8. Current and future treatments for relapsing-remitting multiple sclerosis.
Birnbaum G
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):214-25. PubMed ID: 20205055
[TBL] [Abstract][Full Text] [Related]
9. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
[TBL] [Abstract][Full Text] [Related]
10. Control of multiple sclerosis relapses with immunomodulating agents.
Johnson KP
J Neurol Sci; 2007 May; 256 Suppl 1():S23-8. PubMed ID: 17350652
[TBL] [Abstract][Full Text] [Related]
11. [Pragmatic approach to treatments in multiple sclerosis].
Vermersch P
Rev Neurol (Paris); 2009 Apr; 165 Spec No 2():F125-31. PubMed ID: 19593885
[No Abstract] [Full Text] [Related]
12. B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Rovituso D; Heller S; Schroeter M; Kleinschnitz C; Kuerten S
J Neuroimmunol; 2014 Jul; 272(1-2):86-90. PubMed ID: 24814390
[TBL] [Abstract][Full Text] [Related]
13. Predicting and preventing the future: actively managing multiple sclerosis.
Hutchinson M
Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
[TBL] [Abstract][Full Text] [Related]
14. Natalizumab and beyond.
Yildiz M; Tettenborn B; Putzki N
Eur Neurol; 2010; 64(4):236-40. PubMed ID: 20820105
[No Abstract] [Full Text] [Related]
15. Plasma chitotriosidase activity in multiple sclerosis.
Comabella M; Domínguez C; Rio J; Martín-Gallán P; Vilches A; Vilarrasa N; Espejo C; Montalban X
Clin Immunol; 2009 May; 131(2):216-22. PubMed ID: 19176289
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in relapsing-remitting multiple sclerosis.
Chaudhuri A; Behan PO
N Engl J Med; 2008 Jun; 358(24):2646; author reply 2646-7. PubMed ID: 18557178
[No Abstract] [Full Text] [Related]
17. Glypican 5 is an interferon-beta response gene: a replication study.
Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
[TBL] [Abstract][Full Text] [Related]
18. Comment on "Gender differences in 1,25 dihydroxyvitamin D3 immunomodulatory effects in multiple sclerosis patients and healthy subjects".
Handel AE; De Luca GC; Ramagopalan SV
J Immunol; 2011 Jan; 186(2):647; author reply 648. PubMed ID: 21209286
[No Abstract] [Full Text] [Related]
19. Rituximab in relapsing-remitting multiple sclerosis.
De Palma R; Sementa A
N Engl J Med; 2008 Jun; 358(24):2645-6; author reply 2646-7. PubMed ID: 18550883
[No Abstract] [Full Text] [Related]
20. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis.
Zaffaroni M; Marino F; Bombelli R; Rasini E; Monti M; Ferrari M; Ghezzi A; Comi G; Lecchini S; Cosentino M
Exp Neurol; 2008 Dec; 214(2):315-21. PubMed ID: 18824168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
